VA offers cutting-edge epilepsy treatment
The Department of Veterans Affairs has successfully performed its first-ever minimally invasive laser epilepsy treatment, marking a significant expansion in neurosurgical options available to veterans with drug-resistant focal epilepsy. The groundbreaking procedure took place last week at the Michael E. DeBakey VA Medical Center in Houston, where retired Army National Guard officer Robert Lindemann became the first VA patient to receive treatment using the Visualase V2 system, a technology previously available only at select academic medical centers outside the VA system.
Focal epilepsy affects thousands of veterans, causing seizures that originate from a specific area of the brain. Traditional treatment typically begins with medication, but when multiple drugs fail to control seizures, the standard surgical option has been a craniotomy, an invasive procedure requiring surgeons to remove a significant portion of brain tissue. This conventional approach carries substantial risks, requires lengthy recovery periods, and can impact cognitive function. For many veterans facing this choice, the prospect of major brain surgery has been daunting enough to delay or refuse treatment altogether, leaving them to manage ongoing seizures that disrupt daily life and independence.
The Visualase procedure represents a dramatically different approach to treating drug-resistant focal epilepsy. Instead of opening the skull and removing brain tissue, neurosurgeons insert a fiber optic catheter through a hole just 3.2 millimeters wide, smaller than a pencil eraser. Using real-time MRI guidance, the surgical team delivers precise laser energy to ablate only the problem tissue deep within the brain, monitoring temperatures moment by moment to protect surrounding structures. Dr. Garrett Banks, the neurosurgeon who performed the Houston procedure, emphasized that this technology preserves cognitive abilities and dignity while treating the condition with minimal trauma.
Lindemann's experience illustrates the practical difference this technology makes. After years of failed medication trials and facing the prospect of major brain surgery to remove a large portion of his right temporal lobe, he underwent the laser procedure and was discharged just two days later. Four days after the procedure, he reported feeling great, a stark contrast to the extended recovery that would have followed traditional surgery. His case demonstrates both the safety and effectiveness of bringing this advanced technology into the VA healthcare system.
For disabled veterans living with epilepsy, this development matters because it expands treatment options at a time when neurological conditions remain a significant source of service-connected disability. Epilepsy can develop years after service, sometimes without clear early warning signs, and drug-resistant cases have historically left veterans choosing between uncontrolled seizures and high-risk surgery. The availability of minimally invasive laser ablation within the VA system means veterans can access cutting-edge care without navigating outside referrals or academic medical centers, and with the faster recovery times that preserve independence and quality of life.
According to Dr. Banks, the Houston VA's successful implementation opens possibilities for treating not only focal epilepsy but also deep brain tumors and radiation necrosis across the VA system. While the technology is currently available at the Houston facility, its introduction suggests the potential for broader availability as more VA medical centers develop the necessary expertise and equipment. Veterans currently managing drug-resistant focal epilepsy with their VA neurologists should discuss whether they might be candidates for this type of minimally invasive treatment, particularly if they have been reluctant to pursue traditional surgical options due to the risks and recovery involved.